Marina Scarpelli

Marina Scarpelli

Auto-generated profile, based on publicly available information

Marina Scarpelli

Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, 60126 Ancona, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2020 in Cells
Verified
Journal Article
Open access
PDF file
GAGaetano Aurilio
Gaetano Aurilio
ALESSIA CIMADAMOREALESSIA CIMADAMORE
ALESSIA CIMADAMORE
RMRoberta Mazzucchelli
Roberta Mazzucchelli
ALAntonio Lopez-Beltran
Antonio Lopez-Beltran
EVElena Verri
Elena Verri
RMRodolfo Montironi
Rodolfo Montironi
Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is generally the first therapy adopted. However, the patient’s response to androgen ablation therapy is variable, and 20–30% of PCa cases become castration resistant (CRPCa). Several mechanisms can guide treatment resistance to anti-AR molecules. In this regard, AR-dependent and -independent resistance mechanisms can be distinguished within the AR pathway. In this article, we investigate the multitude of AR signaling aspects, encompassing the biological structure of AR, current AR-targeted therapies, mechanisms driving resistance to AR, and AR crosstalk with other pathways, in an attempt to provide a comprehensive review for the PCa research community. We also summarize the new anti-AR drugs approved in non-metastatic castration-resistant PCa, in the castration-sensitive setting, and combination therapies with other drugs.

8 September 2020 in Cells
Verified
Journal Article
Open access
PDF file
Alessandro RizzoAlessandro Rizzo
Alessandro Rizzo
VMVeronica Mollica
Veronica Mollica
ALESSIA CIMADAMOREALESSIA CIMADAMORE
ALESSIA CIMADAMORE
MSMatteo Santoni
Matteo Santoni
MSMarina Scarpelli
Marina Scarpelli
Francesco MassariFrancesco Massari
Francesco Massari
In the last decade, immunotherapy has revolutionized the treatment landscape of several hematological and solid malignancies, reporting unprecedented response rates. Unfortunately, this is not the case for metastatic castration-resistant prostate cancer (mCRPC), as several phase I and II trials assessing programmed death receptor 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitors have shown limited benefits. Moreover, despite sipuleucel-T representing the only cancer vaccine approved by the Food and Drug Administration (FDA) for mCRPC following the results of the IMPACT trial, the use of this agent is relatively limited in everyday clinical practice. The identification of specific histological and molecular biomarkers that could predict response to immunotherapy represents one of the current challenges, with an aim to detect subgroups of mCRPC patients who may benefit from immune checkpoint monoclonal antibodies as monotherapy or in combination with other anticancer agents. Several unanswered questions remain, including the following: is there—or will there ever be—a role for immunotherapy in prostate cancer? In this review, we aim at underlining the failures and promises of immunotherapy in prostate cancer, summarizing the current state of art regarding cancer vaccines and immune checkpoint monoclonal antibodies, and discussing future research directions in this immunologically “cold” malignancy.

25 April 2020 in Cells
Verified
Journal Article
Open access
PDF file
RMRodolfo Montironi
Rodolfo Montironi
ALESSIA CIMADAMOREALESSIA CIMADAMORE
ALESSIA CIMADAMORE
ALAntonio Lopez-Beltran
Antonio Lopez-Beltran
MSMarina Scarpelli
Marina Scarpelli
GAGaetano Aurilio
Gaetano Aurilio
Liang ChengLiang Cheng
Liang Cheng
The term aggressive variant prostate cancer (AVPCa) refers to androgen receptor (AR)-independent anaplastic forms of prostate cancer (PCa), clinically characterized by a rapidly progressive disease course. This involves hormone refractoriness and metastasis in visceral sites. Morphologically, AVPCa is made up of solid sheets of cells devoid of pleomorphism, with round and enlarged nuclei with prominent nucleoli and slightly basophilic cytoplasm. The cells do not show the typical architectural features of prostatic adenocarcinoma and mimic the undifferentiated carcinoma of other organs and locations. The final diagnosis is based on the immunohistochemical expression of markers usually seen in the prostate, such as prostate-specific membrane antigen (PSMA). A subset of AVPCa can also express neuroendocrine (NE) markers such as chromogranin A, synaptophysin and CD56. This letter subset represents an intermediate part of the spectrum of NE tumors which ranges from small cell to large cell carcinoma. All such tumors can develop following potent androgen receptor pathway inhibition. This means that castration-resistant prostate cancer (CRPCa) transdifferentiates and becomes a treatment-related NE PCa in a clonally divergent manner. The tumors that do not show NE differentiation might harbor somatic and/or germline alterations in the DNA repair pathway. The identification of these subtypes has direct clinical relevance with regard to the potential benefit of platinum-based chemotherapy, poly (ADP-ribose) polymerase inhibitors and likely further therapies.

31 March 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Francesco MassariFrancesco Massari
Francesco Massari
VMVeronica Mollica
Veronica Mollica
VNVINCENZO DI NUNNO
VINCENZO DI NUNNO
LGLidia Gatto
Lidia Gatto
MSMatteo Santoni
Matteo Santoni
GBGiovanni Brandi
Giovanni Brandi
The human microbiome is gaining increasing attention in the medical community, as knowledge on its role not only in health but also in disease development and response to therapies is expanding. Furthermore, the connection between the microbiota and cancer, especially the link between the gut microbiota and gastrointestinal tumors, is becoming clearer. The interaction between the microbiota and the response to chemotherapies and, more recently, to immunotherapy has been widely studied, and a connection between a peculiar type of microbiota and a better response to these therapies and a different incidence in toxicities has been hypothesized. As knowledge on the gut microbiota increases, interest in the residing microbial population in other systems of our body is also increasing. Consequently, the urinary microbiota is under evaluation for its possible implications in genitourinary diseases, including cancer. Prostate cancer is the most common cancer in the male population; thus, research regarding its etiology and possible factors correlated to disease progression or the response to specific therapies is thriving. This review has the purpose to recollect the current knowledge on the relationship between the human microbiota and prostate cancer.

11 January 2019 in Cells
Verified
Journal Article
Open access
PDF file
VMVeronica Mollica
Veronica Mollica
VNVINCENZO DI NUNNO
VINCENZO DI NUNNO
ALESSIA CIMADAMOREALESSIA CIMADAMORE
ALESSIA CIMADAMORE
ALAntonio Lopez-Beltran
Antonio Lopez-Beltran
Liang ChengLiang Cheng
Liang Cheng
Francesco MassariFrancesco Massari
Francesco Massari
Management of metastatic or advanced prostate cancer has acquired several therapeutic approaches that have drastically changed the course of the disease. In particular due to the high sensitivity of prostate cancer cells to hormone depletion, several agents able to inhibit hormone production or binding to nuclear receptor have been evaluated and adopted in clinical practice. However, despite several hormonal treatments being available nowadays for the management of advanced or metastatic prostate cancer, the natural history of the disease leads inexorably to the development of resistance to hormone inhibition. Findings regarding the mechanisms that drive this process are of particular and increasing interest as these are potentially related to the identification of new targetable pathways and to the development of new drugs able to improve our patients’ clinical outcomes.

14 June 2019 in Cancers
Verified
Journal Article
Open access
PDF file
VMVeronica Mollica
Veronica Mollica
VNVINCENZO DI NUNNO
VINCENZO DI NUNNO
LGLidia Gatto
Lidia Gatto
MSMatteo Santoni
Matteo Santoni
MSMarina Scarpelli
Marina Scarpelli
Francesco MassariFrancesco Massari
Francesco Massari
The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with targeted compounds has irreversibly changed clinical scenarios. A deeper knowledge of the molecular mechanisms that correlate with tumor development and progression has made this revolution possible. In this amazing era, novel challenges are awaiting us in the clinical management of metastatic RCC. Of these, the development of reliable criteria which are able to predict tumor response to treatment or primary and acquired resistance to systemic treatments still remain an unmet clinical need. Thanks to the availability of data provided by studies evaluating genomic assessments of the disease, this goal may no longer be out of reach. In this review, we summarize current knowledge about genomic alterations related to primary and secondary resistance to target therapy and immune-checkpoint inhibitors in RCC.